JNCCN Journal of the National Comprehensive Cancer Network
Journal
Overview
publication venue for
-
Nonmelanoma Skin Cancer in Childhood and Young Adult Cancer Survivors Previously Treated With Radiotherapy.
17:237-243.
2019
-
Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer.
17:194-200.
2019
-
Antimicrobial stewardship in patients with cancer: The time is now.
17:772-775.
2019
-
Geriatric oncology education for the oncologist is overdue.
16:336-338.
2018
-
Frequency, morbidity, and mortality of bone metastases in advanced hepatocellular carcinoma.
16:50-58.
2018
-
NCCN Guidelines® insights breast cancer, version 1.2017: Featured updates to the NCCN Guidelines.
15:433-451.
2017
-
Clinical practice guidelines in oncology.
15:230-269.
2017
-
Electronic rapid fitness assessment: A novel tool for preoperative evaluation of the geriatric oncology patient.
15:172-179.
2017
-
Neoadjuvant therapy for rectal cancer affects lymph node yield and status without clear implications on outcome: The case for eliminating a metric and using preoperative staging to guide therapy.
14:1528-1534.
2016
-
Bladder Cancer, Version 2.2016 Featured Updates to the NCCN Guidelines.
14:1213-1224.
2016
-
High Body Mass Index in Elderly Patients with DLBCL Treated with Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex.
14:1274-1281.
2016
-
Ovarian cancer, version 1.2016: Clinical practice guidelines in oncology.
14:1134-63.
2016
-
Genetic/familial high-risk assessment: Colorectal version 1.2016: Clinical practice guidelines in oncology.
14:1010-30.
2016
-
NCCN Guidelines® insights: Melanoma, version 3.2016: Featured updates to the NCCN Guidelines.
14:945-58.
2016
-
Whole-exome sequencing in two extreme phenotypes of response to VEGF-targeted therapies in patients with metastatic clear cell renal cell carcinoma.
14:820-4.
2016
-
NCCN guidelines® insights survivorship, version 1.2016 featured updates to the NCCN Guidelines.
14:715-24.
2016
-
Imatinib treatment of lymphangiomatosis (generalized lymphatic anomaly).
14:383-6.
2016
-
Melanoma, version 2.2016 clinical practice guidelines in oncology.
14:450-73.
2016
-
NCCN guidelines and quality cancer care: Where have we come from, and where should we be going?.
14:373-7.
2016
-
NCCN guidelines® insights multiple myeloma, version 3.2016 featured updates to the NCCN guidelines.
14:389-400.
2016
-
Breast cancer, version 1.2016 featured updates to the NCCN guidelines.
13:1475-85.
2015
-
Prostate cancer early detection, version 2.2015: Clinical practice guidelines in oncology.
13:1534-61.
2015
-
Anemia and functional disability in older adults with cancer.
13:1233-9.
2015
-
Testicular cancer, version 2.2015: Clinical pactice guidelines in oncology.
13:772-99.
2015
-
Emerging treatment options for B-Cell Lymphomas.
13:666-9.
2015
-
Management of dermatologic toxicities.
13:686-9.
2015
-
NCCN roundtable: What are the characteristics of an optimal clinical practice guideline?.
13:640-2.
2015
-
NCCN roundtable:value-based decision-making at the bedside.
13:659-61.
2015
-
Cancer-associated venous thromboembolic disease, version 1.2015: Featured updates to the NCCN Guidelines.
13:1079-95.
2015
-
Central nervous system cancers, version 1.2015: Featured updates to the NCCN guidelines.
13:1191-202.
2015
-
Cervical cancer, version 2.2015: Featured updates to the NCCN guidelines featured updates to the NCCN guidelines.
13:395-404; quiz 404.
2015
-
Guideline familiarity predicts variation in self-reported use of routine surveillance PET/CT by physicians who treat head and neck cancer.
13:69-77.
2015
-
Head and neck cancers, version 1.2015 featured updates to the NCCN guidelines.
13:847-55; quiz 856.
2015
-
Metastatic insulinoma: Current molecular and cytotoxic therapeutic approaches for metastatic well-differentiated panNETs.
13:139-44.
2015
-
Rectal cancer, version 2.2015: Featured updates to the NCCN guidelines.
13:719-28; quiz 728.
2015
-
The right drug for the right patient: Navigating systemic therapy options in metastatic renal cell carcinoma and future directions.
13:1168-70.
2015
-
Hepatobiliary cancers, version 2.2014.
12:1152-82.
2014
-
Survivorship: Immunizations and Prevention of Infections, Version 2.2014.
12:1098-111.
2014
-
Systemic therapy for advanced appendiceal adenocarcinoma: An analysis from the NCCN oncology outcomes database for colorectal cancer.
12:1123-30.
2014
-
False-positive elevations of carcinoembryonic antigen in patients with a history of resected colorectal cancer.
12:907-13.
2014
-
Neoadjuvant radiotherapy use in locally advanced rectal cancer at NCCN member institutions.
12:235-43.
2014
-
Chronic myelogenous leukemia, version 1.2015.
12:1590-610.
2014
-
Diet and physical activity in the prevention of colorectal cancer.
12:1721-6.
2014
-
Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer.
12:513-9.
2014
-
Non-small cell lung cancer, version 1.2015: Clinical practice guidelines in oncology.
12:1738-61.
2014
-
Senior adult oncology, version 2.2014: Clinical practice guidelines in oncology.
12:82-126.
2014
-
Survivorship: Introduction and definition: Clinical practice guidelines in oncology.
12:34-45.
2014
-
Thyroid carcinoma, version 2.2014: Featured updates to the NCCN guidelines.
12:1671-80; quiz 1680.
2014
-
Study using the NCCN guidelines for palliative care to screen patients for palliative care needs and referral to palliative care specialists.
11:1087-96.
2013
-
Breast cancer, version 3.2013.
11:753-60; quiz 761.
2013
-
Systemic therapy for small cell lung cancer.
11:780-7.
2013
-
Metastatic colon cancer, version 3.2013: Featured updates to the NCCN guidelines.
11:141-52; quiz 152.
2013
-
Second-Generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers.
11:161-9.
2013
-
Multiple myeloma, version 1.2013: Featured updates to the NCCN guidelines.
11:11-7.
2013
-
Non-Hodgkin's Lymphomas, version 3.2012: Featured updates to the NCCN guidelines.
10:1487-98.
2012
-
Rectal cancer.
10:1528-64.
2012
-
A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer.
10:1391-8.
2012
-
BRAF mutations in colorectal cancer: Clinical relevance and role in targeted therapy.
10:1456-8.
2012
-
Hypofractionated whole breast radiation and partial breast radiation for early-stage breast cancers: An update on progress.
10:1161-4.
2012
-
Acute myeloid leukemia.
10:984-1021.
2012
-
Modern approaches to localized cancer of the esophagus.
9:902-11.
2011
-
NCCN task force report: Optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy.
9:S1-29.
2011
-
NCCN task force report: Tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia.
9:S1-25.
2011
-
Identifying older patients with acute myeloid leukemia who may be candidates for reduced-intensity hematopoietic cell transplantation.
9:319-29; quiz 330.
2011
-
Fertility-sparing surgery in early-stage cervical cancer: Indications and applications.
8:1435-8.
2010
-
Geographic proximity and racial disparities in cancer clinical trial participation.
8:1343-51.
2010
-
Complications of multiple myeloma therapy, part 2: Risk reduction and management of venous thromboembolism, osteonecrosis of the jaw, renal complications, and anemia.
8:S13-20.
2010
-
Concordance with NCCN colorectal cancer guidelines and ASCO/NCCN quality measures: An NCCN institutional analysis.
7:895-904.
2009
-
Lung cancer screening.
6:271-5.
2008
-
Novel systemic therapies for small cell lung cancer.
6:315-22.
2008
-
Small cell lung cancer.
6:294-314.
2008
-
Point: Combination versus single-agent chemotherapy: The argument for sequential single agents.
5:668-72.
2007
-
NCCN Task Force report: Positron Emission Tomography (PET)/Computed Tomography (CT) scanning in cancer.
5:S1-22; quiz S23-2.
2007
-
Cancer- and treatment-related anemia: Clinical Practice Guidelines in Oncology.
3:772-89.
2005
-
Chronic myelogenous leukemia: Clinical practice guidelines in oncology.
3:732-55.
2005
-
Comparative studies on erythropoietic agents.
3:S46-9.
2005
-
New approaches in the management of lung cancer.
3:S22-4.
2005
-
Proteasome inhibitors in non-Hodgkin's lymphoma.
3:S34-6.
2005
-
Update: NCCN breast cancer clinical practice guidelines.
3:S7-11.
2005
-
Update: NCCN prostate cancer clinical practice guidelines.
3:S29-33.
2005
-
Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II..
2 Suppl 4:S21-2.
2004
-
New advances in taxane therapy: the next generation..
2 Suppl 3:S-5-8.
2004
-
New advances in the treatment of gastric cancer..
2 Suppl 3:S-29-33.
2004
-
Update: NCCN non-small cell lung cancer clinical practice guidelines..
2 Suppl 3:S-9-13.
2004
-
Counterpoint: The case Against adjuvant high-dose interferon-α for melanoma patients.
2:69-72.
2004
-
Prostate cancer: nomograms and risk assessment models..
1 Suppl 3:S-49-54.
2003
-
Update: colorectal cancer guidelines..
1 Suppl 3:S-9-16.
2003
-
Psychological issues in geriatric oncology.
1:381-92.
2003
-
Update: prostate cancer early detection clinical practice guidelines..
1 Suppl 1:S57-60.
2003
-
Hepatobiliary cancers, version 1.2017 featured updates to the NCCN guidelines.
15:563-573.
2017
-
Hodgkin lymphoma version 1.2017.
15:608-638.
2017
-
Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology.
15:504-535.
2017
-
Colon cancer, version 1.2017: Clinical practice guidelines in oncology.
15:370-398.
2017
-
NCCN guidelines® insights chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017: Featured updates to the NCCN guidelines.
15:293-311.
2017
-
Genetic/familial high-risk assessment: Breast and ovarian, version 2.2017: Featured updates to the NCCN guidelines.
15:9-20.
2017
-
Myelodysplastic syndromes, version 2.2017: Clinical practice guidelines in oncology.
15:60-87.
2017
-
Vulvar cancer, version 1.2017: Clinical practice guidelines in oncology.
15:92-120.
2017
-
Myeloproliferative neoplasms, version 2.2017: Clinical Practice Guidelines in oncology.
14:1572-1611.
2016
-
NCCN guidelines® insights: Chronic myeloid leukemia, version 1.2017: Featured updates to the NCCN guidelines.
14:1505-1512.
2016
-
Older adult oncology, version 2.2016: Featured updates to the NCCN guidelines.
14:1357-1370.
2016
-
Gastric Cancer, Version 3.2016; Clinical Practice Guidelines in Oncology.
14:1286-1312.
2016
-
NCCN Guidelines® insights: Non-Hodgkin's lymphomas, version 3.2016 featured updates to the NCCN guidelines.
14:1067-79.
2016
-
NCCN Guidelines®: Insights malignant pleural mesothelioma, version 3.2016.
14:825-36.
2016
-
Prevention and treatment of cancer-related infections, version 2.2016.
14:882-913.
2016
-
Basal cell skin cancer, version 1.2016: Clinical practice guidelines in oncology.
14:574-97.
2016
-
Prostate cancer early detection, Version 2.2016: Featured updates to the NCCN guidelines.
14:509-19.
2016
-
The role of biosimilars.
14:626-9.
2016
-
Invasive breast cancer version 1.2016.
14:324-54.
2016
-
NCCN guidelines® Insights: Non-small cell lung cancer, version 4.2016 Featured updates to the NCCN guidelines.
14:255-64.
2016
-
Diffuse large b-cell lymphoma version 1.2016: Clinical practice guidelines in oncology.
14:196-231.
2016
-
Genetic/familial high-risk assessment: Breast and ovarian, version 2.2015 Featured updates to the NCCN guidelines.
14:153-62.
2016
-
Acute lymphoblastic leukemia, version 2.2015: Clinical practice guidelines in oncology.
13:1240-79.
2015
-
Evaluating the potential role of PET/CT in the posttreatment surveillance of head and neck cancer.
13:252-4.
2015
-
Multiple myeloma, version 2.2016: Clinical practice guidelines in oncology.
13:1398-435.
2015
-
Where exactly does ponatinib fit in chronic myelogenous leukemia?.
12:1615-20.
2014
-
Counterpoint: Prostate-specific antigen velocity is not of value for early detection of cancer.
11:286-90.
2013
-
Clinical practice guidelines in oncology.
9:1238-90.
2011
-
Psychostimulants for cancer-related fatigue.
8:933-942.
2010
-
Colorectal cancer screening: Clinical practice guidelines in oncology™.
8:8-61.
2010
-
Hepatobiliary cancers.
7.
2009
-
Counterpoint: Hyperthermia with radiation therapy for chest wall recurrences.
5:345-8.
2007
-
NCCN Task Force report: Bone health and cancer care.
4:S1-20; quiz S21-2.
2006
-
Elucidation of the molecular mechanisms of malignant bone tumors: Refining diagnosis and identifying novel targets for treatment.
3:142-6.
2005
-
NCCN biosimilars white paper: Regulatory, scientific, and patient safety perspectives
2011
-
NCCN task force report: Bone health in cancer care
2009
-
Antiemesis
2009
-
Uterine neoplasms
2009
-
Bladder cancer
2009
-
Myeloid growth factors
2009
-
Cervical cancer
2008
-
Cervical cancer screening
2008
-
Breast cancer risk reduction: Clinical Practice Guidelines in Oncology™
2007
-
Genetic/familial high-risk assessment: Breast and ovarian. Clinical Practice Guidelines in Oncology™
2006
-
Neuroendocrine tumors: Clinical Practice Guidelines in Oncology™
2006
-
Guidelines for NHL: Updates to the management of diffuse large B-cell lymphoma and new guidelines for primary cutaneous CD30+ T-cell lymphoproliferative disorders and T-cell large granular lymphocytic leukemia.
12:797-800.
2014
-
International adaptation and use of NCCN guidelines.
12:838-41.
2014
-
NCCN Bone Health Task Force: Key recommendations.
12:813-6.
2014
-
Point/counterpoint: Early detection of prostate cancer: Do the benefits outweigh the consequences?.
12:768-71.
2014
-
Evolving roles of histologic evaluation and molecular/genomic profiling in the management of endometrial cancer
2018
-
Emerging role of CAR T cells in Non-Hodgkin's Lymphoma
2017
-
Follow-up management of patients with testicular cancer: A multidisciplinary consensus-based approach
2015
-
Hodgkin Lymphoma, version 2.2015
2015
-
Non-Small cell lung cancer, version 6.2015: Featured updates to the NCCN guidelines
2015
-
Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms
2015
-
Anaplastic thyroid carcinoma, version 2.2015
2015
-
Breast cancer risk reduction, version 2.2015 clinical practice guidelines in oncology clinical practice guidelines in oncology
2015
-
Breast cancer version 2.2015: Clinical practice guidelines in oncology
2015
-
Cancer-related fatigue, version 2.2015
2015
-
Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015
2015
-
Colorectal cancer screening, version 1.2015: Featured updates to the NCCN guidelines
2015
-
Esophageal and esophagogastric junction cancers, Version 1.2015
2015
-
Kidney cancer, version 3.2015: Featured updates to the NCCN guidelines
2015
-
Lung cancer screening, version 1.2015: Featured updates to the NCCN guidelines
2015
-
Myelodysplastic syndromes, version 2.2015 featured updates to the NCCN guidelines
2015
-
Neuroendocrine tumors, version 1.2015
2015
-
Role of repeat resection in non-muscle-invasive bladder cancer
2015
-
Spine radiosurgery in the management of renal cell carcinoma metastases
2015
-
Uterine sarcoma, version 1.2016: Featured updates to the NCCN Guidelines
2015
-
Colon cancer, version 3.2014
2014
-
Occult primary, version 3.2014; Featured updates to the NCCN guidelines
2014
-
Survivorship: Cognitive function, Version 1.2014; Clinical practice guidelines in oncology
2014
-
Dermatofibrosarcoma protuberans, version 1.2014
2014
-
Non-Hodgkin's lymphomas, version 2.2014
2014
-
Survivorship: Fatigue, version 1.2014 - Clinical practice guidelines in oncology
2014
-
Cervical cancer screening
2014
-
Kidney cancer, version 2.2014
2014
-
Sentinel lymph node mapping for endometrial cancer: A modern approach to surgical staging
2014
-
Survivorship: Sexual dysfunction (female), version 1.2013
2014
-
Uterine neoplasms, version 1.2014
2014
-
Breast cancer version 3.2014
2014
-
Central nervous system cancers, Version 2.2014: Featured updates to the NCCN guidelines
2014
-
Genetic/familial high-risk assessment: Breast and ovarian, version 1.2014
2014
-
Head and neck cancers, version 2.2014
2014
-
Melanoma, version 4.2014: Featured updates to the NCCN guidelines
2014
-
Merkel cell carcinoma, version 1.2014.
2014
-
Non-Hodgkin's lymphomas, version 4.2014
2014
-
Palliative care, version 1.2014 featured updates to the NCCN guidelines
2014
-
Pertuzumab in the treatment of HER2+ breast cancer
2014
-
Prostate Cancer,,Version 2.2014 Clinical Practice Guidelines in Oncology
2014
-
Prostate cancer early detection, version 1.2014: Featured updates to the NCCN guidelines
2014
-
Survivorship: Healthy lifestyles, version 2.2014
2014
-
Survivorship: Nutrition and weight management, version 2.2014
2014
-
Survivorship: Pain version 1.2014 - Clinical practice guidelines in oncology
2014
-
Survivorship: Screening for cancer and treatment effects, version 2.2014
2014
-
Survivorship: Sleep disorders, version 1.2014
2014
-
Survivorship: sexual dysfunction (male), version 1.2013.
2014
-
Colorectal cancer screening: Clinical practice guidelines in oncology
2013
-
Postconsolidation maintenance and monitoring in patients with acute promyelocytic leukemia
2013
-
Prostate cancer, version 1.2014: Featured updates to the NCCN Guidelines
2013
-
Chronic myelogenous leukemia, version 1.2014: Featured updates to the NCCN guidelines
2013
-
Translating genomics in cancer care
2013
-
Venous thromboembolic disease: Clinical Practice Guidelines in Oncology
2013
-
Ovarian cancer, version 2.2013: Featured updates to the NCCN guidelines
2013
-
Acute myeloid leukemia, version 2.2013 featured updates to the NCCN guidelines
2013
-
Central nervous system cancers
2013
-
Adult cancer pain
2013
-
Head and Neck Cancers, version 2.2013
2013
-
NCCN task force report: Bone health in cancer care
2013
-
Non-small cell lung cancer, version 2.2013: Featured updates to the NCCN guidelines
2013
-
Bladder cancer: Clinical practice guidelines in oncology
2013
-
Gastric cancer, version 2.2013
2013
-
Localized Colon Cancer, version 3.2013
2013
-
Melanoma, version 2.2013: Featured updates to the NCCN guidelines
2013
-
Thymomas and thymic carcinomas
2013
-
Progress in the management of melanoma in 2013
2013
-
Recent advances in the treatment of non-Hodgkin's lymphomas
2013
-
Systemic therapy for metastatic colorectal cancer
2013
-
Cervical cancer: Clinical practice guidelines in oncology
2013
-
Non-Hodgkin's lymphomas, version 1.2013: Featured updates to the NCCN guidelines
2013
-
Distress Management: Clinical practice guidelines in oncology
2013
-
Impact of the 7th edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers
2013
-
Penile cancer
2013
-
Small cell lung cancer: Clinical practice guidelines in oncology
2013
-
Ovarian cancer, version 3.2012: Featured updates to the NCCN guidelines
2012
-
Prevention and treatment of cancer-related infections
2012
-
Non-small cell lung cancer: Clinical practice guidelines in oncology
2012
-
Palliative care: Clinical practice guidelines in oncology
2012
-
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013: Featured updates to the NCCN guidelines
2012
-
Prostate cancer, version 3.2012: Featured updates to the NCCN Guidelines
2012
-
Acute lymphoblastic leukemia: Clinical practice guidelines in oncology
2012
-
Exocrine pancreas cancer and thromboembolic events: A systematic literature review
2012
-
Metastatic breast cancer, version 1.2012: Featured updates to the NCCN guidelines
2012
-
Neuroendocrine tumors: Clinical practice guidelines in oncology
2012
-
Systemic therapy for advanced pancreatic neuroendocrine tumors: An update
2012
-
Cancer- and chemotherapy-induced anemia: Clinical practice guidelines in oncology
2012
-
Hodgkin lymphoma, version 2.2012: Featured updates to the NCCN guidelines
2012
-
The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement
2012
-
Anal carcinoma, version 2.2012: Featured updates to the NCCN guidelines
2012
-
Antiemesis
2012
-
Late cardiovascular toxicity following chemotherapy for germ cell tumors
2012
-
Testicular cancer
2012
-
Controversies in the management of regional nodes in melanoma
2012
-
Dermatofibrosarcoma protuberans
2012
-
Melanoma
2012
-
Mucosal melanoma of the head and neck
2012
-
Lung cancer screening: Clinical practice guidelines in oncology
2012
-
Senior adult oncology: Clinical practice guidelines in oncology
2012
-
Chronic myelogenous leukemia
2012
-
Malignant pleural mesothelioma
2012
-
Novel therapies in phase II and III trials for malignant pleural mesothelioma
2012
-
NCCN molecular testing white paper: Effectiveness, efficiency, and reimbursement
2011
-
Occult primary
2011
-
Colon cancer.
2011
-
Multiple myeloma clinical practice guidelines in oncology
2011
-
Small cell lung cancer clinical practice guidelines in oncology
2011
-
Surgery for early-stage small cell lung cancer
2011
-
Hodgkin lymphoma: Clinical practice guidelines in oncology
2011
-
Kidney cancer
2011
-
Esophageal and esophagogastric junction cancers
2011
-
Venous thromboembolic disease: Clinical practice guidelines in oncology
2011
-
Current recommendations for systemic therapy of recurrent and/or metastatic head and neck squamous cell cancer
2011
-
Head and neck cancers: Clinical practice guidelines in oncology
2011
-
Non-Hodgkin's lymphomas: Clinical practice guidelines in oncology
2011
-
A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma
2011
-
Central nervous system cancers: Clinical practice guidelines in oncology
2011
-
Acute myeloid leukemia: Clinical practice guidelines in oncology
2011
-
Invasive breast cancer: Clinical practice guidelines in oncology
2011
-
Epithelial ovarian cancer
2011
-
Cervical Cancer Screening Clinical Practice Guidelines in Oncology
2010
-
Cervical cancer: Clinical practice guidelines in oncology
2010
-
Thymic malignancies
2010
-
Thyroid carcinoma
2010
-
Breast cancer risk reduction
2010
-
Breast cancer: Noninvasive and special situations
2010
-
Adult cancer pain: Clinical practice guidelines in oncology
2010
-
Basal cell and squamous cell skin cancers
2010
-
Cancer-related fatigue
2010
-
Modification and implementation of NCCN guidelines on lymphomas in the Middle East and North Africa region.
2010
-
Non-small cell lung cancer: Clinical practice guidelines in oncology
2010
-
Genetic/familial high-risk assessment: Breast and ovarian - Clinical practice guidelines in oncology™
2010
-
Medullary carcinoma: Clinical practice guidelines in oncology™
2010
-
Distress management: Clinical practice guidelines in oncology™
2010
-
Gastric cancer: A primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease
2010
-
Gastric cancer: Clinical practice guidelines in oncology™
2010
-
An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma
2010
-
Non-Hodgkin's lymphomas clinical practice guidelines in oncology
2010
-
Prostate cancer: Clinical practice guidelines in oncology™
2010
-
Anal carcinoma: Clinical practice guidelines in oncology™
2010
-
NCCN clinical practice guidelines in oncology. Colorectal cancer screening.
2010
-
Breast cancer screening and diagnosis: Clinical practice guidelines in oncology™
2009
-
NCCN task force report: Management of neuropathy in cancer
2009
-
Chronic myelogenous leukemia
2009
-
Multiple myeloma
2009
-
Colon cancer
2009
-
Rectal cancer
2009
-
NCCN Task Force report: Molecular markers in leukemias and lymphomas
2009
-
NCCN Task Force: Clinical utility of PET in a variety of tumor types
2009
-
Neuroendocrine tumors
2009
-
Kidney cancer
2009
-
Testicular cancer
2009
-
NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer
2009
-
NCCN clinical practice guidelines in oncology: hepatobiliary cancers.
2009
-
Selection of patients with hepatocellular carcinoma for sorafenib
2009
-
Melanoma
2009
-
Merkel cell carcinoma
2009
-
Breast cancer: Clinical Practice Guidelines in Oncology™
2009
-
Integrating perioperative chemotherapy into the treatment of muscle-invasive bladder cancer: Strategy versus reality
2009
-
Acute myeloid leukemia
2008
-
Occult primary: Clinical practice guidelines in oncology
2008
-
Strategy for incorporating molecular and cytogenetic markers into acute myeloid leukemia therapy
2008
-
Esophageal cancer
2008
-
Myelodysplastic syndromes
2008
-
Ovarian cancer
2008
-
Venous thromboembolic disease
2008
-
Head and neck cancers
2008
-
The role of inhibitors of the epidermal growth factor in management of head and neck cancer
2008
-
NCCN Task Force report: Breast cancer in the older woman
2008
-
Cancer- and chemotherapy-induced anemia
2008
-
Hodgkin disease/lymphoma
2008
-
Central nervous system cancers: Clinical Practice Guidelines in Oncology™
2008
-
NCCN Task Force Report: Oral chemotherapy
2008
-
Non-small cell lung cancer
2008
-
Non-Hodgkin's lymphomas
2008
-
Review of the treatment of mycosis fungoides and Sézary syndrome: A stage-based approach
2008
-
Prevention and treatment of cancer-related infections
2008
-
NCCN task force report: Prevention and management of mucositis in cancer care
2008
-
Cancer-related fatigue clinical practice guidelines in oncology
2007
-
Update on psychotropic medications for cancer-related fatigue
2007
-
Colon cancer
2007
-
Rectal cancer
2007
-
Targeted strategies in the treatment of metastatic colon cancer
2007
-
Prostate cancer
2007
-
Investigational therapies for metastatic thyroid carcinoma
2007
-
Thyroid carcinoma
2007
-
Basal cell and squamous cell skin cancers
2007
-
Chronic myelogenous leukemia
2007
-
Dermatofibrosarcoma protuberans
2007
-
Bone cancer: Clinical Practice Guidelines in Oncology™
2007
-
The NCCN. Invasive breast cancer: Clinical practice guidelines in oncology™
2007
-
Growth factors in leukemia
2007
-
Multiple myeloma: Clinical practice guidelines in oncology™
2007
-
Myeloid growth factors: Clinical practice guidelines in oncology™
2007
-
Antiemesis: Clinical practice guidelines in Oncology™
2007
-
Distress management: Clinical practice guidelines in Oncology™
2007
-
Bladder cancer clinical practice guidelines in oncology
2006
-
Importance of node dissection in relation to neoadjuvant and adjuvant therapy
2006
-
Kidney cancer clinical practice guidelines in oncology
2006
-
Testicular cancer clinical practice guidelines in oncology
2006
-
Ovarian cancer: Clinical Practice Guidelines in Oncology™
2006
-
Venous thromboembolic disease: Clinical practice guidelines in Oncology™
2006
-
Hepatobiliary cancers clinical practice guidelines in oncology
2006
-
Melanoma: Clinical practice guidelines in oncology™
2006
-
Merkel cell carcinoma: Clinical practice guidelines in oncology™
2006
-
Role of dermatologists in treating melanoma
2006
-
Non-small cell lung cancer: Clinical Practice Guidelines in Oncology™
2006
-
Pulmonary neuroendocrine tumors: What (little) do we know?
2006
-
Small cell lung cancer: Clinical Practice Guidelines in Oncology™
2006
-
Uterine cancers: Clinical practice guidelines in oncology™
2006
-
Colorectal cancer screening: Clinical Practice Guidelines in oncology™
2006
-
Esophageal cancer: Clinical Practice Guidelines in oncology™
2006
-
Gastric cancer: Clinical Practice Guidelines in oncology™
2006
-
Favorable early-stage Hodgkin lymphoma
2006
-
Hodgkin disease/lymphoma: Clinical practice guidelines in oncology™
2006
-
Non-Hodgkin's lymphoma: Clinical practice guidelines in oncology™
2006
-
Acute myeloid leukemia: Clinical Practice Guidelines in Oncology
2006
-
Myelodysplastic syndromes: Clinical Practice Guidelines in Oncology
2006
-
Strategies for the treatment of acute promyelocytic leukemia
2006
-
Central nervous system cancers Clinical Practice Guidelines in Oncology
2005
-
Anal canal cancer clinical practice guidelines in oncology
2005
-
Colon cancer clinical practice guidelines
2005
-
Rectal cancer clinical practice guidelines in oncology
2005
-
Breast cancer: Clinical practice guidelines in oncology
2005
-
Head and neck cancers: Clinical practice guidelines
2005
-
Partial-breast radiation for early staged breast cancers: Hypothesis, existing data, and a planned phase III trial
2005
-
Thyroid carcinoma: Clinical practice guidelines
2005
-
Bone cancer: Clinical practice guidelines
2005
-
Occult primary cancer: Clinical practice guidelines
2005
-
Bladder cancer: Clinical practice guidelines in oncology
2005
-
Kidney cancer: Clinical practice guidelines
2005
-
Testicular cancer: Clinical practice guidelines
2005
-
The integration of chemotherapy and surgery for bladder cancer
2005
-
Cervical cancer guidelines. Clinical practice guidelines in oncology.
2004
-
Cervical cancer screening clinical practice guidelines in oncology.
2004
-
Ovarian cancer clinical practice guidelines.
2004
-
Antiemesis clinical practice guidelines in oncology.
2004
-
Fever and neutropenia clinical practice guidelines.
2004
-
Non-Hodgkin's lymphoma clinical practice guidelines.
2004
-
Surgery in the management of small cell lung cancer
2004
-
Point: Sentinel lymph node biopsy is indicated for patients with DCIS
2003
-
Controversies in the surgical management of gastric cancer
2003
-
Anal canal cancer. Clinical practice guidelines in oncology.
2003
-
Anemia clinical practice guidelines in oncology.
2003
-
Colon cancer. Clinical practice guidelines in oncology.
2003
-
Rectal cancer. Clinical practice guidelines in oncology.
2003
-
Ten years of progress in head and neck cancers
2012
-
Ten years of progress in renal cell carcinoma
2012
-
Incorporation of crizotinib into the NCCN guidelines
2011
-
Lessons from ASH 2010: A focus on NHL
2011
-
In defense of hepatic arterial infusion for hepatic metastases of colorectal cancer: Commentary
2010
Identity
ISO Abbreviation
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)